2024 Disease Molecular Biology Pharma Companies 
Drug Discovery World
MAY 1, 2024
DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024. Artificial intelligence (AI) AI is on everyone’s minds as we head into 2024; of course, this is across not just the drug discovery spectrum but is particularly relevant to therapeutic antibodies.
Drug Discovery World
MAY 6, 2024
A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. So, in this way there is a cross fertilisation from the bigger companies to newer ones.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Vial
MARCH 1, 2024
from 2024 to reach US$129.8 Recent advancements In February 2024, PPD announced the addition of mycoplasma and biosafety testing capabilities to its good manufacturing practices (GMP) lab in Wisconsin, US. It ensures regulatory compliance for over 15 long-term post-authorization safety studies across eight disease indications.
Elrig
APRIL 29, 2024
Joining Isomorphic Labs in October 2024, I’m thrilled to be part of their mission to revolutionize DD through AI/ML. Jasmine has a background in neuroscience and genetic manipulation, with early works focused on using a combined structural and molecular biology approach to assess disease-associated proteins implicated in Alzheimer’s disease.
Codon
FEBRUARY 13, 2024
alone, according to the Centers for Disease Control and Prevention. ” A Global View Even as advances in computing and molecular biology usher in the era of a new, high-tech “phage therapy 2.0”, At least a million people die from drug-resistant bacterial infections every year.
Expert insights. Personalized for you.
148 
Let's personalize your content